Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) has received a consensus rating of "Hold" from the five analysts that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $38.6667.
Several research firms have weighed in on PHAR. Oppenheimer reiterated an "outperform" rating on shares of Pharming Group in a report on Thursday, July 30th. Canaccord Genuity Group boosted their price target on shares of Pharming Group from $37.00 to $38.00 and gave the company a "buy" rating in a report on Monday, August 3rd. Wall Street Zen cut shares of Pharming Group from a "strong-buy" rating to a "hold" rating in a research report on Saturday, May 9th. Zacks Research downgraded Pharming Group from a "hold" rating to a "strong sell" rating in a research note on Friday, July 31st. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Pharming Group in a report on Friday, August 7th.
View Our Latest Analysis on PHAR
Pharming Group Price Performance
Pharming Group stock opened at $11.83 on Thursday. The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $837.33 million, a P/E ratio of 98.58 and a beta of -0.01. The business has a 50-day moving average of $12.70 and a 200-day moving average of $14.75. Pharming Group has a 1 year low of $9.62 and a 1 year high of $21.34.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by ($0.04). The firm had revenue of $90.20 million during the quarter, compared to analyst estimates of $99.52 million. Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. On average, equities analysts anticipate that Pharming Group will post 0.25 EPS for the current year.
Hedge Funds Weigh In On Pharming Group
Several institutional investors have recently modified their holdings of PHAR. EverSource Wealth Advisors LLC acquired a new position in shares of Pharming Group in the 2nd quarter valued at approximately $32,000. SmartHarvest Portfolios LLC acquired a new stake in Pharming Group during the 4th quarter worth approximately $224,000. Millennium Management LLC acquired a new stake in Pharming Group during the 4th quarter worth approximately $360,000. Finally, NewEdge Advisors LLC lifted its stake in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company's stock valued at $510,000 after buying an additional 28,615 shares in the last quarter. Institutional investors own 0.03% of the company's stock.
About Pharming Group
(
Get Free Report)
Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.
The company's lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
